Company intelligence / Profile preview
Syena
Houston, Texas, United Statessynatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Syena was launched in February 2023 by Replay and The University of Texas MD Anderson Cancer Center to pioneer first-in-class engineered allogeneic T-cell receptor natural killer (TCR-NK) cell therapies. Its lead asset—cord blood-derived NK cells expressing an affinity-enhanced NY‑ESO‑1-specific TCR—entered a Phase 1/2 study for multiple myeloma patients in early/mid 2024. The company has rapidly expanded its pipeline through exclusive licenses covering additional tumor antigens including PRAME, KRAS, p53, HPV16, MAGE family members. Early results are not yet public but the platform aims to combine the safety/scalability advantages of allogeneic NK cells with the intracellular target reach of engineered TCRs—a next-generation approach beyond CAR-T/CAR-NK therapies.
- Therapeutic areas
- Oncology
- Modalities
- Engineered TCR-NK cell therapies (T-cell receptor natural killer cells)Allogeneic ("off-the-shelf") cell therapies derived from cord blood NK cellsPotentially additional engineered immune cell modalities via partnerships and licensing agreements
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Miltenyi BiotecJURA BioNational Institutes of Health/National Cancer Institute
Beyond the preview
Go deeper on Syena.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syena.